Podocyte-specific VEGF-A gain of function induces nodular glomerulosclerosis in eNOS null mice

Journal of the American Society of Nephrology

Volumn 25, Issue 8, 2014, Pages 1814-1824

  Veron, Delma ^a   Aggarwal, Pardeep K ^a   Velazquez, Heino ^a   Kashgarian, Michael ^a   Moeckel, Gilbert ^a   Tufro, Alda ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; COLLAGEN TYPE 4; CREATININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LAMININ; VASCULOTROPIN A; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; HYALINE DEGENERATION; KIDNEY FAILURE; KIDNEY FUNCTION; MICROANEURYSM; MOUSE; NITROSYLATION; NODULAR GLOMERULOSCLEROSIS; NONHUMAN; PHENOTYPE; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEINURIA; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; ANIMAL; CULTURE TECHNIQUE; DIABETIC NEPHROPATHIES; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; RENAL INSUFFICIENCY;

ANIMALS; CELL CULTURE TECHNIQUES; COLLAGEN TYPE IV; DIABETIC NEPHROPATHIES; GLOMERULAR BASEMENT MEMBRANE; LAMININ; MICE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE III; PODOCYTES; PROTEINURIA; RENAL INSUFFICIENCY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908330530     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013070752     Document Type: Article

References (61)

1. Coultas L, Chawengsaksophak K, Rossant J: Endothelial cells and VEGF in vascular development. Nature 438: 937-945, 2005
2. Tufro A, Norwood VF, Carey RM, Gomez RA: Vascular endothelial growth factor induces nephrogenesis and vasculogenesis. J Am Soc Nephrol 10: 2125-2134, 1999
3. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707-716, 2003
4. Veron D, Reidy K, Marlier A, Bertuccio C, Villegas G, Jimenez J, Kashgarian M, Tufro A: Induction of podocyte VEGF164 overexpression at different stages of development causes congenital nephrosis or steroid-resistant nephrotic syndrome. Am J Pathol 177: 2225-2233, 2010
5. VeronD,Reidy KJ,BertuccioC,Teichman J, VillegasG, Jimenez J, ShenW, Kopp JB, Thomas DB, Tufro A: Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int 77: 989-999, 2010
6. Veron D, Bertuccio CA, Marlier A, Reidy K, Garcia AM, Jimenez J, Velazquez H, Kashgarian M, Moeckel GW, Tufro A: Podocyte vascular endothelial growth factor (Vegf) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia 54: 1227-1241, 2011
7. Tufro A, Veron D: VEGF and podocytes in diabetic nephropathy. Semin Nephrol 32: 385-393, 2012
8. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001
9. Bredt DS, Hwang PM, Snyder SH: Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 347: 768-770, 1990
10. Pollock JS, Förstermann U, Mitchell JA, Warner TD, Schmidt HH, Nakane M, Murad F: Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci U S A 88: 10480-10484, 1991
11. Kone BC, Baylis C: Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Am J Physiol 272: F561-F578, 1997
12. Wilcox CS, Deng X, Welch WJ: NO generation and action during changes in salt intake: roles of nNOS and macula densa. Am J Physiol 274: R1588-R1593, 1998
13. Bachmann S, Bosse HM, Mundel P: Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidney. Am J Physiol 268: F885-F898, 1995
14. Bachmann S, Mundel P: Nitric oxide in the kidney: synthesis, localization, and function. Am J Kidney Dis 24: 112-129, 1994
15. Tanimoto T, Jin ZG, Berk BC: Transactivation of vascular endothelial phosphate-stimulated phosphorylation of Akt and endothelial nitricoxide synthase (eNOS). J Biol Chem 277: 42997-43001, 2002
16. Papapetropoulos A, García-Cardeña G, Madri JA, Sessa WC: Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100: 3131-3139, 1997
17. Tsurumi Y, Murohara T, Krasinski K, Chen D, Witzenbichler B, Kearney M, Couffinhal T, Isner JM: Reciprocal relation between VEGF andNOin the regulation of endothelial integrity. Nat Med 3: 879-886, 1997
18. Gao N, Ding M, Zheng JZ, Zhang Z, Leonard SS, Liu KJ, Shi X, Jiang BH: Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J Biol Chem 277: 31963-31971, 2002
19. Feliers D, Chen X, Akis N, Choudhury GG, Madaio M, Kasinath BS: VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells. Kidney Int 68: 1648-1659, 2005
20. Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM: Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 97: 99-107, 1998
21. Nakayama T, Sato W, Kosugi T, Zhang L, Campbell-Thompson M, Yoshimura A, Croker BP, Johnson RJ, Nakagawa T: Endothelial injury due to eNOS deficiency accelerates the progression of chronic renal disease in themouse.AmJ Physiol Renal Physiol 296: F317-F327, 2009
22. Brodsky SV, Gao S, Li H, Goligorsky MS: Hyperglycemic switch from mitochondrial nitric oxide to superoxide production in endothelial cells. Am J Physiol Heart Circ Physiol 283: H2130-H2139, 2002
23. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M: Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108: 1341-1348, 2001
24. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH: Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes.JAmSocNephrol 12: 993-1000, 2001
25. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R: Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51: 3090-3094, 2002
26. Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, Yuzawa Y, Atkinson MA, Johnson RJ, Croker B: Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 18: 539-550, 2007
27. Yuen DA, Stead BE, Zhang Y, White KE, Kabir MG, Thai K, Advani SL, Connelly KA, Takano T, Zhu L, Cox AJ, Kelly DJ, Gibson IW, Takahashi T, Harris RC, Advani A: eNOS deficiency predisposes podocytes to injury in diabetes. J Am Soc Nephrol 23: 1810-1823, 2012
28. Cheng H, Wang H, Fan X, Paueksakon P, Harris RC: Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice. Kidney Int 82: 1176-1183, 2012
29. Friebe A, Koesling D: Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 93: 96-105, 2003
30. Stamler JS, Lamas S, Fang FC: Nitrosylation. The prototypic redoxbased signaling mechanism. Cell 106: 675-683, 2001
31. Lima B, Forrester MT, Hess DT, Stamler JS: S-nitrosylation in cardiovascular signaling. Circ Res 106: 633-646, 2010
32. Hess DT, Stamler JS: Regulation by S-nitrosylation of protein posttranslational modification. J Biol Chem287: 4411-4418, 2012
33. Anand P, Stamler JS: Enzymatic mechanisms regulating protein Snitrosylation: implications in health and disease. J MolMed (Berl) 90: 233-244, 2012
34. Jaffrey SR, Snyder SH: The biotin switch method for the detection of Snitrosylated proteins. Sci STKE 2001: pl1, 2001
35. Zhao HJ, Wang S, Cheng H, Zhang MZ, Takahashi T, Fogo AB, Breyer MD, Harris RC: Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice.JAmSocNephrol 17: 2664-2669, 2006
36. Guan F, Villegas G, Teichman J, Mundel P, Tufro A: Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am J Physiol Renal Physiol 291: F422-F428, 2006
37. Bertuccio C, Veron D, Aggarwal PK, Holzman L, Tufro A: Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes. J Biol Chem286: 39933-39944, 2011
38. Veron D, Villegas G, Aggarwal PK, Bertuccio C, Jimenez J, Velazquez H, Reidy K, Abrahamson DR, Moeckel G, Kashgarian M, Tufro A: Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphaVbeta3 integrin signaling in the glomerulus. PLoSONE 7: e40589, 2012
39. Saito Y, Kida H, Takeda S, Yoshimura M, Yokoyama H, Koshino Y, Hattori N: Mesangiolysis in diabetic glomeruli: its role in the formation of nodular lesions. Kidney Int 34: 389-396, 1988
40. Kosugi T, Heinig M, Nakayama T, Connor T, Yuzawa Y, Li Q, Hauswirth WW, GrantMB, Croker BP, Campbell-Thompson M, Zhang L, Atkinson MA, Segal MS, Nakagawa T: Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice. Am J Pathol 174: 1221-1229, 2009
41. Karalliedde J, Gnudi L: Endothelial factors and diabetic nephropathy. Diabetes Care 34[Suppl 2]: S291-S296, 2011
42. Nakagawa T: Uncoupling of VEGF with NOas amechanismfor diabetic nephropathy. Diabetes Res Clin Pract 82[Suppl 1]: S67-S69, 2008
43. Kanetsuna Y, Takahashi K, Nagata M, Gannon MA, Breyer MD, Harris RC, Takahashi T: Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. Am J Pathol 170: 1473-1484, 2007
44. SatoW, Kosugi T, Zhang L, Roncal CA, HeinigM, Campbell-Thompson M, Yuzawa Y, Atkinson MA, Grant MB, Croker BP, Nakagawa T: The pivotal role of VEGF on glomerularmacrophage infiltration in advanced diabetic nephropathy. Lab Invest 88: 949-961, 2008
45. Gilkeson GS, Mashmoushi AK, Ruiz P, Caza TN, Perl A, Oates JC: Endothelial nitric oxide synthase reduces crescentic and necrotic glomerular lesions, reactive oxygen production, and MCP1 production in murine lupus nephritis. PLoS ONE 8: e64650, 2013
46. Morishita T, Tsutsui M, Shimokawa H, Sabanai K, Tasaki H, Suda O, Nakata S, Tanimoto A, Wang KY, Ueta Y, Sasaguri Y, Nakashima Y, Yanagihara N: Nephrogenic diabetes insipidus in mice lacking all nitric oxidesynthase isoforms.ProcNatlAcadSciUSA102: 10616-10621,2005
47. Tsutsui M, Shimokawa H, Otsuji Y, Yanagihara N: Pathophysiological relevance of NO signaling in the cardiovascular system: novel insight from mice lacking all NO synthases. Pharmacol Ther 128: 499-508, 2010
48. Erwin PA, Lin AJ, Golan DE, Michel T: Receptor-regulated dynamic Snitrosylation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem280: 19888-19894, 2005
49. Erwin PA,Mitchell DA, Sartoretto J, Marletta MA,Michel T: Subcellular targeting and differential S-nitrosylation of endothelial nitric-oxide synthase. J Biol Chem 281: 151-157, 2006
50. Thibeault S, Rautureau Y, Oubaha M, Faubert D, Wilkes BC, Delisle C, Gratton JP: S-nitrosylation of beta-catenin by eNOS-derived NO promotes VEGF-induced endothelial cell permeability. Mol Cell 39: 468-476, 2010
51. Dobson CM: Experimental investigation of protein folding and misfolding. Methods 34: 4-14, 2004
52. Cheng YS, Champliaud MF, Burgeson RE, Marinkovich MP, Yurchenco PD: Self-assembly of laminin isoforms. J Biol Chem272: 31525-31532, 1997
53. Chen YM, Kikkawa Y, Miner JH: A missense LAMB2 mutation causes congenital nephrotic syndrome by impairing laminin secretion. J Am Soc Nephrol 22: 849-858, 2011
54. Liu L, Doné SC, Khoshnoodi J, Bertorello A, Wartiovaara J, Berggren PO, Tryggvason K: Defective nephrin trafficking caused by missense mutations in the NPHS1 gene: insight into the mechanisms of congenital nephrotic syndrome. Hum Mol Genet 10: 2637-2644, 2001
55. Howard M,Welch WJ: Manipulating the folding pathway of delta F508 CFTR using chemical chaperones. Methods Mol Med 70: 267-275, 2002
56. Nakamura T, Cho DH, Lipton SA: Redox regulation of protein misfolding, mitochondrial dysfunction, synaptic damage, and cell death in neurodegenerative diseases. Exp Neurol 238: 12-21, 2012
57. Setty S,Michael AA, Fish AJ,MichaelMauer S, Butkowski RJ, Virtanen I, Kim Y: Differential expression of laminin isoforms in diabetic nephropathy and other renal diseases. Mod Pathol 25: 859-868, 2012
58. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, Sherman PA, Sessa WC, Smithies O: Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 93: 13176-13181, 1996
59. Reidy KJ, Aggarwal PK, Jimenez JJ, Thomas DB, Veron D, Tufro A: Excess podocyte semaphorin-3A leads to glomerular disease involving plexinA1-nephrin interaction. Am J Pathol 183: 1156-1168, 2013
60. Söderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J, Wester K, Hydbring P, Bahram F, Larsson LG, Landegren U: Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 3: 995-1000, 2006
61. Akimoto Y, Miura Y, Toda T, Wolfert MA, Wells L, Boons GJ, Hart GW, Endo T, Kawakami H: Morphological changes in diabetic kidney are associated with increased O-GlcNAcylation of cytoskeletal proteins including a-actinin 4. Clin Proteomics 8: 15, 2011